Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Janssen Biotech, the R&D arm of Johnson & Johnson, will pay Japan’s Astellas Pharma $65 million for access to ASP015K, a JAK inhibitor in Phase II trials as a rheumatoid arthritis treatment. Janssen, which gains rights to develop the small-molecule compound everywhere but Japan, will pay for future clinical studies. Astellas could reap another $880 million in milestone and royalty payments if ASP015K reaches the market. Pfizer is awaiting FDA approval for tofacitinib, its own JAK inhibitor for arthritis.
This article has been sent to the following recipient: